Taurohyodeoxycholic acid

Synonyms: 牛磺猪去氧胆酸
Taurohyodeoxycholic acid 是一种口服有效的 6α-羟基化胆汁酸,可降低结肠髓过氧化物酶 (MPO) 活性、TNF-α、IL-6 血清水平以及 COX-2 的表达,通过调节 Th1/Th2 和 Th17/Treg 细胞平衡缓解三硝基苯磺酸诱导的溃疡性结肠炎,改善高脂饮食诱导的小鼠非酒精性脂肪肝病,并能预防 Taurochenodeoxycholic acid (MS-B47892) 诱导的胆瘘大鼠肝毒性,可用于非酒精性脂肪肝病 (NAFLD)、结肠炎和胆瘘的研究。
产品编号: MS-E78965 纯度: 99.73% CAS No.: 2958-04-5 分子式: C26H45NO6S 分子量: 499.70
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
3-5 天
100mg
询价
询价
200mg
询价
询价
500mg
询价
询价

产品描述

Taurohyodeoxycholic acid 是一种口服有效的 6α-羟基化胆汁酸,可降低结肠髓过氧化物酶 (MPO) 活性、TNF-α、IL-6 血清水平以及 COX-2 的表达,通过调节 Th1/Th2 和 Th17/Treg 细胞平衡缓解三硝基苯磺酸诱导的溃疡性结肠炎,改善高脂饮食诱导的小鼠非酒精性脂肪肝病,并能预防 Taurochenodeoxycholic acid (MS-B47892) 诱导的胆瘘大鼠肝毒性,可用于非酒精性脂肪肝病 (NAFLD)、结肠炎和胆瘘的研究。

生物实验数据

生物活性 Taurohyodeoxycholic acid is an orally active 6α-hydroxylated bile acid that reduces colonic myeloperoxidase (MPO) activity, serum levels of TNF-α and IL-6, and COX-2 expression, alleviates trinitrobenzene sulfonic acid-induced ulcerative colitis by modulating the Th1/Th2 and Th17/Treg cell balance, ameliorates high-fat diet-induced non-alcoholic fatty liver disease in mice, prevents Taurochenodeoxycholic acid (MS-B47892)-induced hepatotoxicity in bile duct-cannulated rats, and can be used for research on non-alcoholic fatty liver disease (NAFLD), colitis, and biliary fistula.
体外研究
(In Vitro)

Taurohyodeoxycholic acid (25-100 μM, 12 h) 在棕榈酸 (Palmitic acid (HY-N08307))/油酸 (Oleic acid (MS-M89265)) 处理的 AML-12 细胞中呈剂量依赖性降低甘油三酯水平。

体内研究
(In Vivo)

Taurohyodeoxycholic acid (200 mg/kg,每日口服给药,持续 17 天) 通过减少脂质蓄积改善高脂饮食诱导的小鼠非酒精性脂肪肝病。
Taurohyodeoxycholic acid (20-100 mg/kg,每日口服给药或灌胃给药,持续 7 天) 可以缓解三硝基苯磺酸 (TNBS) 诱导的小鼠结肠炎。
Taurohyodeoxycholic acid (4 mg/kg/min (8 μmol/min/kg),静脉注射 1 小时) 可预防牛磺鹅去氧胆酸 (Taurochenodeoxycholic acid) (MS-B47892) 诱导的胆瘘大鼠肝毒性。

Animal Model: High-fat diet was fed to 4-week-old male C57BL/6 mice to induce nonalcoholic fatty liver disease.
Dosage: 200 mg/kg
Administration: p.o. daily for 17 days
Result: Reduced body weight, liver index, and epididymal white adipose tissue index in high-fat diet-fed mice.
Decreased serum triglyceride, total cholesterol, and hepatic triglyceride levels.
Improved hepatic steatosis and glucose homeostasis (enhanced glucose tolerance and insulin sensitivity).
Upregulated hepatic CYP7B1 protein expression and downregulated hepatic CYP7A1 and CD36 protein expressions.
Dose-dependently decreased triglyceride levels in palmitic acid/oleic acid-treated AML-12 cells.
Animal Model: Trinitrobenzene sulfonic acid (100 μL of 2.0 mg TNBS in 50% EtOH) was intrarectally administered to 7-8-week-old male SPF Kunming mice to induce ulcerative colitis.
Dosage: 20, 40, 80 mg/kg
Administration: p.o. daily for 7 days
Result: Alleviated TNBS-induced colitis by improving body weight, colon length, spleen weight, histological characteristics, and reducing MPO activity in mice.
Reduced Th1-/Th17-related cytokines (IFN-γ, IL-12, p70, IL-6, IL-17A, IL-21, IL-22, TNF-α) and transcription factors (T-bet, STAT4, RORγt, STAT3) in the colon.
Increased Th2-/Treg-related cytokines (IL-4, IL-10, TGF-β1) and transcription factors (GATA3, STAT6, Foxp3, Smad3) in the colon.
Inhibited IFN-γ, IL-17A, T-bet, RORγt expressions and improved IL-4, IL-10, GATA3, Foxp3 expressions in the spleen.
Restored the proportion of Th1, Th2, Th17, Treg cells and balanced Th1/Th2 and Th17/Treg immune response in colitis mice.
Animal Model: Taurochenodeoxycholic acid was intravenously infused into bile fistula Sprague-Dawley rats (200-250 g).
Dosage: 4 mg/kg/min (8 μmol/min/kg)
Administration: i.v. for 1 h
Result: Increased bile flow, with maximum flow rate twice that of the control group after 60 minutes.
Enhanced biliary secretion of total bile acids, reaching a maximum rate of 17.5 μmol/min/kg at 60 minutes; Increased phospholipid secretion, with a peak of 0.65 μmol/min/kg.
Restored biliary calcium secretion; reduced biliary leakage of alkaline phosphatase to levels similar to the control group and decreased lactate dehydrogenase leakage.
Increased the maximum biliary secretion rate of taurochenodeoxycholic acid to 7.6 μmol/min/kg, with its own maximum secretion rate reaching 7.9 μmol/min/kg.
Animal Model: Trinitrobenzene sulfonic acid (TNBS, 0.5 mg in 0.1 ml of 50% ethanol) was intrarectally administered into the colon of 22-25 g male Balb/c mice via a 3.5F catheter inserted 4 cm proximal to the anus to induce ulcerative colitis model.
Dosage: 25, 50, 100 mg/kg
Administration: i.g., daily for 7 days
Result: Alleviated TNBS-induced colitis by improving body weight, reducing macroscopic colonic damage and histopathological changes, and decreasing colonic MPO activity in mice.
Reduced serum levels of pro-inflammatory cytokines (TNF-α, IL-6) and decreased the expression of COX-2 in the colon.
性状 固体
颜色 White to off-white

化学信息

分子量 499.70
分子式 C26H45NO6S
CAS No. 2958-04-5
别名 牛磺猪去氧胆酸

储存&溶解度

体内实验配方
10% DMSO+90% Saline: 10 mg/mL (20.01 mM), Solution.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 100 mg/mL (200.12 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM2.0012 mL10.0060 mL20.0120 mL50.0300 mL
5 mM0.4002 mL2.0012 mL4.0024 mL10.0060 mL
10 mM0.2001 mL1.0006 mL2.0012 mL5.0030 mL
15 mM0.1334 mL0.6671 mL1.3341 mL3.3353 mL
20 mM0.1001 mL0.5003 mL1.0006 mL2.5015 mL
25 mM0.0800 mL0.4002 mL0.8005 mL2.0012 mL
30 mM0.0667 mL0.3335 mL0.6671 mL1.6677 mL
40 mM0.0500 mL0.2502 mL0.5003 mL1.2508 mL
50 mM0.0400 mL0.2001 mL0.4002 mL1.0006 mL
60 mM0.0334 mL0.1668 mL0.3335 mL0.8338 mL
80 mM0.0250 mL0.1251 mL0.2502 mL0.6254 mL
100 mM0.0200 mL0.1001 mL0.2001 mL0.5003 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础